China's Sinovac Covid-19 booster weaker against Omicron - Hong Kong study
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Tuesday
February 07, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
TUESDAY, FEBRUARY 07, 2023
China's Sinovac Covid-19 booster weaker against Omicron - Hong Kong study

Coronavirus chronicle

Reuters
24 December, 2021, 11:10 am
Last modified: 24 December, 2021, 11:18 am

Related News

  • First case of new Covid sub-variant Omicron BF.7 detected in Bangladesh: IEDCR
  • Pfizer expects to hike US Covid vaccine price to $110-$130 per dose
  • US donates 10 million more Pfizer Covid shots to Bangladesh
  • White House urges Covid boosters to protect against spreading BA.5 subvariant
  • US medical experts call for Omicron-specific Covid boosters

China's Sinovac Covid-19 booster weaker against Omicron - Hong Kong study

Their analysis revealed Pfizer-BioNTech vaccine was more effective, as a third dose of the shot administered after two doses of the same or China's Sinovac vaccine provided "protective levels" of antibody against Omicron

Reuters
24 December, 2021, 11:10 am
Last modified: 24 December, 2021, 11:18 am
FILE PHOTO: An employee holds a vial containing CoronaVac, Sinovac Biotech's vaccine against the coronavirus disease (COVID-19), at Butantan biomedical production center in Sao Paulo, Brazil January 12, 2021. REUTERS/Amanda Perobelli
FILE PHOTO: An employee holds a vial containing CoronaVac, Sinovac Biotech's vaccine against the coronavirus disease (COVID-19), at Butantan biomedical production center in Sao Paulo, Brazil January 12, 2021. REUTERS/Amanda Perobelli

Three doses of Sinovac's CoronaVac Covid-19 vaccine do not produce adequate levels of antibodies to fight the Omicron variant of the coronavirus, researchers from Hong Kong said in a statement.

Their analysis revealed Pfizer-BioNTech vaccine was more effective, as a third dose of the shot administered after two doses of the same or China's Sinovac vaccine provided "protective levels" of antibody against Omicron.

Pfizer (PFE.N) and its German partner BioNTech have said their three-shot course was able to neutralise the new Omicron variant in a laboratory test.

The latest study was conducted by researchers from the University of Hong Kong and the Chinese University of Hong Kong, and funded by the Health and Medical Research Fund and the Government of Hong Kong.

The statement did not say how many samples were used in the analysis. Sinovac did not immediately respond to a request for comment.

Sinovac's CoronaVac and state-owned Sinopharm's BBIBP-CorV vaccine are the two most-used vaccines in China and the leading Covid-19 vaccines exported by the country. Sinopharm also has a second vaccine in use in China.

Hong Kong has been using the Sinovac and Pfizer-BioNTech shots. But people aged 12-17 are eligible only for the BioNTech vaccine.

Sinovac Covid-19 Vaccine / Pfizer Covid-19 Vaccine / Omicron Covid variant

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • A man stands in front of collapsed buildings following an earthquake in Kahramanmaras, Turkey February 6, 2023. Ihlas News Agency (IHA) via REUTERS ATTENTION EDITORS - THIS PICTURE WAS PROVIDED BY A THIRD PARTY. NO RESALES. NO ARCHIVES. TURKEY OUT. NO COMMERCIAL OR EDITORIAL SALES IN TURKEY.
    Deaths exceed 2,600 as catastrophic quakes ravage Turkey, Syria
  • 30% cos see double-digit growth even in hard times
    30% cos see double-digit growth even in hard times
  • Govt borrowing from commercial banks surges
    Govt borrowing from commercial banks surges

MOST VIEWED

  • Tourists ride a tour bus in Hong Kong, China October 25, 2019. REUTERS/Ammar Awad
    Hong Kong says 'hello' to woo back visitors after Covid
  • People wearing face masks following the coronavirus disease (Covid-19) outbreak are seen at Beijing Daxing International Airport in Beijing, China July 23, 2020. Photo:Reuters
    Pandemic to paradise: Chinese tourists return to Bali after three years
  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs

Related News

  • First case of new Covid sub-variant Omicron BF.7 detected in Bangladesh: IEDCR
  • Pfizer expects to hike US Covid vaccine price to $110-$130 per dose
  • US donates 10 million more Pfizer Covid shots to Bangladesh
  • White House urges Covid boosters to protect against spreading BA.5 subvariant
  • US medical experts call for Omicron-specific Covid boosters

Features

Photo: Collected

Get your partner a lovely present this Valentine's Day

19h | Brands
Pottery Wheel Craft Kit: A creative outlet for little hands

Pottery Wheel Craft Kit: A creative outlet for little hands

18h | Brands
Say it with Colours

Say it with Colours

1d | Mode
Photo: Courtesy

From 'Made in Bangladesh' to 'Designed in Bangladesh'

1d | Panorama

More Videos from TBS

Who will survive? Adani or Hindenburg?

Who will survive? Adani or Hindenburg?

9h | TBS Stories
James Gunn’s 8-10-year plan for the DC Universe

James Gunn’s 8-10-year plan for the DC Universe

9h | TBS Entertainment
LC issues lead to severe shortage of surgical equipment

LC issues lead to severe shortage of surgical equipment

13h | TBS Insight
Stage plays are going on in the digital age

Stage plays are going on in the digital age

17h | TBS Stories

Most Read

1
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

2
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

3
Belal Ahmed new acting chairman of SIBL
Banking

Belal Ahmed new acting chairman of SIBL

4
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

5
Photo: Collected
Startups

ShopUp secures $30m debt financing to boost expansion, supply chain

6
Photo: Courtesy
Panorama

From 'Made in Bangladesh' to 'Designed in Bangladesh'

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net